Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Van ECK Associates Corp

Van ECK Associates Corp raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 944,978 shares of the company’s stock after acquiring an additional 36,239 shares during the quarter. Van ECK Associates Corp owned approximately 0.19% of Elanco Animal Health worth $11,444,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares during the period. Atom Investors LP lifted its holdings in Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after buying an additional 261,559 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after buying an additional 209,734 shares during the period. Wellington Management Group LLP grew its stake in shares of Elanco Animal Health by 19.2% in the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after acquiring an additional 646,522 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Elanco Animal Health by 14.0% during the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after acquiring an additional 45,795 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ELAN shares. Leerink Partners initiated coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Morgan Stanley lowered their price target on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $16.29.

Elanco Animal Health Stock Down 3.4 %

ELAN stock opened at $11.26 on Friday. The company’s 50 day moving average is $11.94 and its two-hundred day moving average is $13.15. Elanco Animal Health Incorporated has a twelve month low of $10.77 and a twelve month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a market cap of $5.57 billion, a P/E ratio of 28.15, a PEG ratio of 2.69 and a beta of 1.42.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.